GCIA
APGN

Gabelli & Co Investment Advisers’s Apexigen, Inc. Common Stock APGN Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio APGN Stock Details APGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,100
Closed -$111K – 538
2021
Q4 		$111K Buy
+11,100
New +$111K 0.01% 379
2021
Q3 		– Sell
-11,100
Closed -$110K – 503
2021
Q2 		$110K Buy
+11,100
New +$110K 0.01% 365

Other funds holding APGN

PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 20.06% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.62% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $469M AUM 32.23% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Gabelli & Co Investment Advisers's APGN Position: Q1 2022 in Review

Gabelli & Co Investment Advisers sold out of Apexigen, Inc. Common Stock (APGN) in Q1 2022, closing a stake of 11,100 shares — an estimated $111K sold.

Gabelli & Co Investment Advisers first reported a position in APGN in Q2 2021 and held it in 2 quarters. The position peaked at $111K in Q4 2021. 40 funds tracked by Wall St. Rank hold APGN as of Q1 2022.

  • Gabelli & Co Investment Advisers reported no remaining Apexigen, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 11,100 Apexigen, Inc. Common Stock shares in Q1 2022, an estimated $111K.
  • Gabelli & Co Investment Advisers first reported a position in Apexigen, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • Gabelli & Co Investment Advisers's Apexigen, Inc. Common Stock position peaked at $111K in Q4 2021.
  • 40 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q1 2022.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2022, filed 13 May 2022.